Loubeau P R, Loubeau J M, Jantzen R
Iona College, New Rochelle, NY, USA.
Prog Transplant. 2001 Dec;11(4):291-7. doi: 10.1177/152692480101100411.
Using 1998 data for 8 transplantation centers located in New York City, this study found that kidney transplantation was a more cost-effective treatment than hemodialysis for the Medicare program. The initially higher costs of transplantation were fully recouped by Medicare 2 years and 10 months after surgery. For persons who are eligible for Medicare solely due to their end-stage renal disease status, transplantation would generate average monthly savings of $3800 over dialysis for the 2 years following the break-even point. For those eligible for reasons other than end-stage renal disease, for example, the aged, the average savings would be $2400. The savings difference arises because Medicare coverage for immunosuppressants for the former group ends 36 months after transplantation.
利用纽约市8个移植中心的1998年数据,本研究发现,对于医疗保险计划而言,肾移植是比血液透析更具成本效益的治疗方法。移植最初较高的费用在术后2年零10个月时由医疗保险全额收回。对于仅因终末期肾病状况而符合医疗保险资格的人,在收支平衡点后的2年里,移植相对于透析每月平均可节省3800美元。对于因终末期肾病以外的原因(如老年人)而符合资格的人,平均节省额为2400美元。出现节省差异的原因是,前一组患者移植后36个月,医疗保险对免疫抑制剂的覆盖就结束了。